Elizabeth P. Bhatt brings more 25 years of strategy, deal-making and company-building experience across a range of biotech and pharmaceutical companies. Ms. Bhatt currently serves as Chief Operating Officer at Septerna since June 2022. Ms. Bhatt was previously Chief Business & Strategy Officer at Applied Molecular Transport (AMTI) where she oversaw corporate development, portfolio and project management, and commercial strategy. Prior to AMT, Ms. Bhatt was Chief Operating Officer at Achaogen where she led various strategic and operational functions. Prior to Achaogen, Ms. Bhatt spent over a decade at Gilead Sciences as VP, Corporate Development leading deals across all therapeutic areas. She also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises and supported the launch of several products. Ms. Bhatt has also held corporate development and strategy roles at Eli Lilly and Maxygen and started her career in research at Affymax. She currently serves as an independent director on the board of eFFECTOR Therapeutics. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California, San Diego and a M.B.A. from the Kellogg School of Management at Northwestern University.